Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Navigator Medicines

Request full access

Navigator Medicines leads the advancement of biologics for targeted immune regulation & restoration

San Mateo, United StatesFounded 2024Biotech & Life Sciences

About Navigator Medicines

Navigator Medicines is a clinical-stage biopharmaceutical company focused on developing targeted biologics for immune regulation and restoration. Launched in 2024 as a subsidiary of Sera Medicines, the Scotch Plains, New Jersey-based firm is channeling its resources toward creating new treatments for patients with complex and heterogeneous autoimmune diseases. The company's establishment was marked by a significant milestone in August 2024, when it secured $100 million in a Series A financing round co-led by prominent venture capital firms RA Capital Management and Forbion. This funding is primarily dedicated to advancing its lead asset, NAV-240.

The company's core strategy revolves around in-licensing and developing promising antibody therapeutics. In June 2024, Navigator licensed its lead candidate, NAV-240 (formerly IMB-101), from the South Korean biotech IMBiologics. The agreement gives Navigator rights to the asset outside of Asia (but including Japan) for an upfront payment of $20 million, with potential for future milestone payments. This strategic move positions Navigator to address a substantial market, with the global immunology market projected to grow significantly. The company's business model is centered on the clinical development and potential commercialization of its licensed assets, targeting unmet medical needs in the autoimmune sector. Key figures in the company's leadership include CEO and President Tausif 'Tosh' Butt, who was formerly president at Idorsia, and Chief Medical Officer Dr. Dana McClintock, who brings experience from Genentech.

Navigator's lead product, NAV-240, is a clinical-stage bispecific antibody that simultaneously targets two validated pathways in inflammatory diseases: OX40L and TNFα. This dual-targeting mechanism is designed to modulate both the adaptive and innate immune responses, potentially offering superior efficacy compared to therapies that target only one pathway. By blocking both OX40L and TNFα, NAV-240 aims to provide a more effective treatment option for complex conditions like rheumatoid arthritis, including for patients who do not respond to existing anti-TNF agents. The company's pipeline also includes NAV-242, a next-generation version of the anti-OX40L/TNFα antibody with an extended half-life, and other preclinical assets targeting the OX40L pathway. The first participants in a Phase 1b trial for NAV-240 were dosed in May 2025, a key step toward planned patient studies.

Source: Dealroom company data

At a glance

Status
Operational
Employees
27
Open positions
5
Dealroom signal
27.0/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Healthcare Services, Biotechnology, Medical & Healthcare, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES AOther financing Aug 2024 $100M $400M RA Capital Management · Forbion Capital Partners ↗
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Navigator Medicines website traffic

Latest recorded traffic for Navigator Medicines is 1.6K monthly website visits, down 44.8% over the last three months.

Latest monthly visits1.6K 3-month web change-44.8%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Navigator Medicines in the San Mateo ecosystem

Live from Dealroom

The Navigator Medicines office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States94.4%
🇳🇱 Netherlands5.6%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Navigator Medicines on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Navigator Medicines’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.